| Literature DB >> 29343776 |
Seung Min Chung1, Jung Hyun Oh2, Jun Sung Moon3, Yu Kyung Kim4, Ji Sung Yoon1, Kyu Chang Won1, Hyoung Woo Lee1.
Abstract
Critical shear stress (CSS, mPa) is an index of red blood cell (RBC) aggregability, defined as the minimal shear stress required to disperse RBC aggregates. This study aimed to investigate the association between CSS and the risk of diabetic kidney disease (DKD). A total of 421 (mean age, 58.1 ± 11.5 years; male, 250) individuals with T2DM were enrolled and divided into three groups according to CSS level. CSS was measured using a transient microfluidic technique. DKD was defined as a glomerular filtration rate (GFR) <60 ml/min/1.73 m2 or a urine albumin-to-creatinine ratio (uACR) ≥30 mg/g. CSS was significantly higher in patients with DKD than in those without (317.43 ± 125.11 vs 385.22 ± 182.89, p < 0.001). Compared to the lowest CSS tertile, the highest CSS tertile was independently associated with the risk of DKD after adjusting for age, sex, duration of diabetes, presence of hypertension and haemoglobin. The cut-off value of CSS for DKD was approximately 310 mPa. These results suggest that haemorheologic changes may contribute to DKD, and further prospective studies are warranted to determine the role of CSS as a DKD screening tool.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29343776 PMCID: PMC5772353 DOI: 10.1038/s41598-018-19274-5
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Comparison of CSS values according to diabetic microvascular complications. NPDR, non proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy; DPN, diabetic polyneuropathy *p < 0.001.
Baseline Characteristics of Patients based on eGFR (n = 421).
| eGFR (mL/min/1.73 m2) | P-value | ||
|---|---|---|---|
| ≥60 (n = 345) | <60 (n = 76) | ||
| Sex (M:F) | 1.5:1 | 1.30:1 | 0.588 |
| Age (Yrs) | 56.36 ± 11.11 | 66.03 ± 9.85 | <0.001 |
| BMI (Kg/m2) | 24.99 ± 7.47 | 23.84 ± 3.43 | 0.070 |
| Diabetes duration (Yrs) | 7.16 ± 7.22 | 13.69 ± 9.37 | <0.001 |
| HTN (n(%)) | 180 (53.4) | 62 (82.7) | <0.001 |
| FPG (mg/dL) | 165.64 ± 52.34 | 176.35 ± 67.27 | 0.299 |
| HbA1c (%) | 8.19 ± 2.02 | 8.77 ± 2.67 | 0.098 |
| HOMA-IR | 4.52 ± 3.79 | 4.51 ± 2.50 | 0.981 |
| HOMA-B | 48.19 ± 37.72 | 46.89 ± 46.92 | 0.860 |
| Hb (g/dL) | 14.37 ± 1.54 | 12.51 ± 1.86 | <0.001 |
| T-Cho (mg/dL) | 181.27 ± 44.23 | 173.26 ± 55.29 | 0.241 |
| HDL-Cho (mg/dL) | 51.76 ± 13.91 | 47.10 ± 15.54 | 0.020 |
| LDL-Cho (mg/dL) | 96.12 ± 38.66 | 90.04 ± 46.38 | 0.299 |
| TG (mg/dL) | 169.61 ± 110.06 | 184.16 ± 114.05 | 0.322 |
| ESR (mm/H) | 20.01 ± 20.83 | 40.67 ± 28.80 | <0.001 |
| hsCRP (mg/dL) | 0.28 ± 0.71 | 0.57 ± 1.30 | 0.099 |
| Fibrinogen (mg/dL) | 311.21 ± 54.78 | 338.44 ± 58.57 | 0.018 |
| CSS (mPa) | 317.43 ± 125.11 | 385.22 ± 182.89 | <0.001 |
| EI@3Pa (%) | 30.60 ± 1.91 | 30.42 ± 20.54 | 0.481 |
| Fibrinogen/EI@3Pa (mg/dL%) | 1038.28 ± 197.76 | 1141.44 ± 268.71 | 0.045 |
| DR (%) | 32.0 | 46.5 | 0.019 |
| DPN (%) | 15.4 | 29.3 | 0.004 |
| CAD (%) | 8.4 | 23.7 | <0.001 |
BMI, body mass index; HTN, hypertension; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HOMA-IR/B, homeostasis model assessment of insulin resistance/beta-cell function; Hb, hemoglobin; T-cho, total-cholesterol; HDL/LDL-cho, high/low density lipoprotein cholesterol; TG, triglyceride; ESR, erythrocyte sedimentation rate; hs-CRP, high sensitivity c-reactive protein; CSS, critical shear stress; EI@3Pa, elongation index at 3pascal; DR, diabetic retinopathy; DPN, diabetic peripheral neuropathy; CAD, coronary artery disease.
Baseline characteristics of patients based on uACR(n = 390).
| uACR (mg/g) | P for trend | |||
|---|---|---|---|---|
| <30 (n = 259) | 30–300 (n = 100) | >300 (n = 31) | ||
| Sex (M:F) | 1.23:1 | 1.56:1 | 2.88:1 | 0.104 |
| Age (Yrs) | 57.78 ± 11.20 | 58.98 ± 11.84 | 57.32 ± 11.69 | 0.625 |
| BMI (Kg/m2) | 24.62 ± 3.38 | 25.18 ± 12.32 | 25.12 ± 5.44 | 0.813 |
| Diabetes duration (Yrs) | 7.35 ± 7.20 | 8.82 ± 8.95* | 14.12 ± 9.12¶ | <0.001 |
| SBP (mmHg) | 129.15 ± 15.37 | 136.94 ± 14.56* | 137.20 ± 21.189* | <0.001 |
| DBP (mmHg) | 76.58 ± 10.65 | 80.65 ± 10.76* | 81.63 ± 12.20* | 0.001 |
| FPG (mg/dL) | 163.56 ± 52.73 | 172.47 ± 51.38 | 200.50 ± 81.63* | 0.012 |
| HbA1c (%) | 7.98 ± 1.93 | 8.914 ± 2.28 | 8.88 ± 2.68* | <0.001 |
| HOMA-IR | 4.45 ± 3.37 | 4.96 ± 4.65 | 4.20 ± 1.89 | 0.957 |
| HOMA-B | 47.61 ± 34.96 | 51.73 ± 51.40 | 31.95 ± 21.56 | 0.204 |
| Hb (g/dL) | 14.24 ± 1.59 | 13.83 ± 1.84* | 13.31 ± 2.28 | 0.006 |
| T-Cho (mg/dL) | 179.90 ± 41.92 | 169.71 ± 48.04* | 204.81 ± 65.20¶ | 0.001 |
| HDL-Cho (mg/dL) | 52.67 ± 14.01 | 48.70 ± 13.93 | 53.15 ± 14.32* | 0.051 |
| LDL-Cho (mg/dL) | 95.25 ± 35.84 | 86.10 ± 43.92 | 110.43 ± 55.21¶ | 0.010 |
| TG (mg/dL) | 163.77 ± 104.92 | 174.36 ± 127.64 | 206.16 ± 113.86 | 0.126 |
| ESR (mm/H) | 22.71 ± 23.31 | 27.45 ± 27.85 | 51.00 ± 22.91* | 0.017 |
| hs-CRP (mg/dL) | 0.22 ± 0.45 | 0.49 ± 1.08* | 0.44 ± 1.53 | 0.027 |
| Fibrinogen (mg/dL) | 308.55 ± 55.16 | 318.47 ± 48.96* | 363.60 ± 61.64¶ | 0.001 |
| CSS (mPa) | 308.34 ± 118.14 | 349.13 ± 137.35* | 422.45 ± 212.72*¶ | <0.001 |
| EI@3Pa (%) | 30.63 ± 18.75 | 30.57 ± 19.91* | 29.64 ± 27.27 | 0.027 |
| Fibrinogen/EI@3Pa (mg/dL%) | 1022.31 ± 192.56 | 1064.36 ± 182.01* | 1289.07 ± 319.01¶ | <0.001 |
| DR (%) | 27.6 | 46.3 | 54.8 | <0.001 |
| DPN (%) | 14.7 | 23.5 | 22.6 | 0.111 |
| CAD (%) | 10.4 | 11 | 16.1 | 0.632 |
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HOMA-IR/B, homeostasis model assessment of insulin resistance/beta-cell function; Hb, hemoglobin; T-cho, total-cholesterol; HDL/LDL-cho, high/low density lipoprotein cholesterol; TG, triglyceride; ESR, erythrocyte sedimentation rate; hs-CRP, high sensitivity c-reactive protein; CSS, critical shear stress; EI@3Pa, elongation index at 3pascal; DR, diabetic retinopathy; DPN, diabetic peripheral neuropathy; CAD, coronary artery disease.
*p < 0.05 vs. uACR <30 group, ¶p < 0.05 vs. uACR 30–300 group by post-hoc analysis.
Odds ratios(95% CI) for DKD according to CSS.
| Dependent variable: eGFR <60 ml/min/1.73 m2 | ||||
|---|---|---|---|---|
| crude | Model1 | Model2 | Model3 | |
| CSS | 1.003(1.001–1.005) * | 1.003(1.002–1.005)* | 1.004(1.002–1.006)* | 1.003(1.001–1.005)* |
| CSS T1 | 1(ref) | 1(ref) | 1(ref) | 1(ref) |
| CSS T2 | 1.101(0.554–2.191) | 1.398(0.673–2.902) | 1.202(0.537–2.691) | 2.010(0.793–5.089) |
| CSS T3 | 2.265(1.207–4.253)* | 2.727(1.383–5.377)* | 2.134(0.983–4.632) | 2.573(1.057–6.264)* |
|
| ||||
|
|
|
|
| |
| CSS | 1.003(1.001–1.005)* | 1.003(1.002–1.005)* | 1.003(1.002–1.005)* | 1.003(1.001–1.005)* |
| CSS T1 | 1(ref) | 1(ref) | 1(ref) | 1(ref) |
| CSS T2 | 1.638(0.927–2.896) | 1.641(0.925–2.912) | 1.344(0.723–2.499) | 1.451(0.772–2.730) |
| CSS T3 | 3.046(1.743–5.324)* | 3.244(1.841–5.716)* | 3.129(1.684–5.815)* | 3.063(1.632–5.748)* |
Model 1, adjusted for Age, Gender; Model 2, adjusted as in Model 1 plus diabetes duration and hypertension; Model 3, adjusted as in Model 2 plus Hb.
*p < 0.05, T, tercile; Ref, reference range.